Aspira Women's Health (AWH) 10-K 31 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 24, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Entity Registrant Name	VERMILLION, INC.
Entity Central Index Key	926,617
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 31,814,733
Entity Common Stock, Shares Outstanding		56,089,245

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 5,242	$ 18,642
Accounts receivable	275	87
Prepaid expenses and other current assets	498	550
Inventories	93	87
Total current assets	6,108	19,366
Property and equipment, net	1,911	1,504
Other assets		90
Total assets	8,019	20,960
Current liabilities:
Accounts payable	881	988
Accrued liabilities	1,464	2,208
Short-term debt	182
Other Current Liabilities	34	155
Total current liabilities	2,561	3,351
Long-term debt	1,667
Other non-current liabilities	29	63
Total liabilities	4,257	3,414
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding at December 31, 2016 and 2015
Common stock, $0.001 par value, 150,000,000 shares authorized; 52,328,492 and 52,113,059 shares issued and outstanding at December 31, 2016 and 2015, respectively	52	52
Additional paid-in capital	389,266	388,082
Accumulated deficit	(385,556)	(370,588)
Total stockholders' equity	3,762	17,546
Total liabilities and stockholders' equity	$ 8,019	$ 20,960

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Consolidated Balance Sheets [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	52,328,492	52,113,059
Common stock, shares outstanding	52,328,492	52,113,059

Consolidated Statements Of Oper

Consolidated Statements Of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue:
Product	$ 2,320	$ 1,861
Service	322
License		316
Total revenue	2,642	2,177
Cost of revenue:
Product	1,974	2,309
Service	724
Total cost of revenue	2,698	2,309
Gross loss	(56)	(132)
Operating expenses:
Research and development	2,172	3,751
Sales and marketing	6,798	9,833
General and administrative	5,928	5,533
Total operating expenses	14,898	19,117
Loss from operations	(14,954)	(19,249)
Interest (expense) income, net	(28)	28
Other income (expense), net	14	106
Net loss	$ (14,968)	$ (19,115)
Net loss per share - basic and diluted	$ (0.29)	$ (0.41)
Weighted average common shares used to compute basic and diluted net loss per common share	52,197,969	47,124,261

Consolidated Statements Of Ope5

Consolidated Statements Of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cost Of Revenue [Member]
Stock-based compensation expense	$ 115	$ 40
Research And Development [Member]
Stock-based compensation expense	71	137
Sales And Marketing [Member]
Stock-based compensation expense	108	209
General And Administrative [Member]
Stock-based compensation expense	$ 885	$ 841

Consolidated Statements Of Chan

Consolidated Statements Of Changes In Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance (in shares) at Dec. 31, 2014	43,115,790
Balance at Dec. 31, 2014	$ 43	$ 370,685	$ (351,473)	$ 19,255
Net loss			(19,115)	(19,115)
Common stock issued in conjunction with follow-on public offering, net of issuance costs (in shares)	9,602,500
Common stock issued in conjunction with follow-on public offering, net of issuance costs	$ 10	17,363		$ 17,373
Common stock issued in conjuntion with exercise of stock options (in shares)	59,583			59,583
Common stock issued in conjuntion with execise of stock options		97		$ 97
Common stock issued for restricted stock awards (in shares)	195,781
Common stock issued for restricted stock awards		401		401
Stock compensation charge		826		826
Repurchase of common stock (in shares)	(860,595)
Repurchase of common stock	$ (1)	(1,290)		(1,291)
Balance (in shares) at Dec. 31, 2015	52,113,059
Balance at Dec. 31, 2015	$ 52	388,082	(370,588)	17,546
Net loss			(14,968)	$ (14,968)
Common stock issued in conjuntion with exercise of stock options (in shares)	3,541			3,541
Common stock issued in conjuntion with execise of stock options		5		$ 5
Common stock issued for restricted stock awards (in shares)	211,892
Common stock issued for restricted stock awards		334		334
Stock compensation charge		845		845
Balance (in shares) at Dec. 31, 2016	52,328,492
Balance at Dec. 31, 2016	$ 52	$ 389,266	$ (385,556)	$ 3,762

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (14,968)	$ (19,115)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on extinguishment of debt		(37)
Non-cash license revenue		(316)
Loss on sale and disposal of property and equipment	6
Depreciation and amortization	723	291
Stock-based compensation expense	1,179	1,227
Changes in operating assets and liabilities:
Accounts receivable	(188)	80
Prepaid expenses and other assets	142	(106)
Inventories	(6)	(87)
Accounts payable, accrued liabilities and other liabilities	(851)	(129)
Deferred revenue		(173)
Net cash used in operating activities	(13,963)	(18,365)
Cash flows from investing activities:
Purchase of property and equipment	(1,261)	(282)
Construction in progress		(773)
Net cash used in investing activities	(1,261)	(1,055)
Cash flows from financing activities:
Repurchase of common stock		(1,291)
Issuance costs related to 2014 private placement		(122)
Proceeds from public offering of common stock, net of issuance costs		17,495
Repayment of short-term debt		(1,069)
Proceeds from issuance of DECD loan, net of issuance costs	1,967
Principal repayment of DECD loan	(118)
Repayment of capital lease obligations	(30)	(13)
Proceeds from issuance of common stock from exercise of stock options	5	97
Net cash provided by financing activities	1,824	15,097
Net decrease in cash and cash equivalents	(13,400)	(4,323)
Cash and cash equivalents, beginning of year	18,642	22,965
Cash and cash equivalents, end of year	5,242	18,642
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	38	7
Supplemental disclosure of noncash investing and financing activities:
Equipment acquired through capital lease agreements		107
Changes in other current liabilities related to equipment		$ 125

Basis Of Presentation And Signi

Basis Of Presentation And Significant Accounting And Reporting Policies	12 Months Ended
	Dec. 31, 2016
Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]
Basis Of Presentation And Significant Accounting And Reporting Policies	NOTE 1: Basis of Presentation and Summary of Significant Accounting and Reporting Policies Organization Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells the OVA1™ and Overa ™ risk of malignancy test s for ovarian cancer (“OVA1” and “Overa” ). Until August 10, 2015, the Company distributed OVA1 through Quest Diagnostics Incorporated (“Quest Diagnostics”) (see Note 3). Since August 10, 2015, the Company has distributed all tests through Vermillion’s wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, ASPiRA LABS, Inc . (“ASPiRA LABS”). The Company also offers in-vitro diagnostic (“IVD”) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (“ASPiRA IVD”), which was formed in April 2016. ASPiRA IVD is a specialized, CLIA certified, laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize high-complexity assays. ASPiRA IVD was built around a core of laboratory expertise and a United States Food and Drug Administration (“FDA”)-compliant quality system, and strives to deliver accurate and reliable results to its third-party customers suitable for FDA submission.  Liquidity I n July 2015 the Company completed the sale of 9,602,500 shares of Vermillion common stock, at a price to the public of $1.96 per share, including 1,252,500 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, in an underwritten public offering at a price of $1.96 per share. Net proceeds from the offering were approximately $17,495,000 after deducting underwriting discounts and offering expenses. As discussed in Note 6, on March 22, 2016, the Company entered into a loan agreement (the “Loan Agreement”) pursuant to which it may borrow up to $4,000,000 from the State of Connecticut Department of Economic and Community Development (“DECD”). An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. The remaining $2,000,000 will be advanced if and when the Company achieves certain future milestones. On February 17, 2017 , the Company completed a private placement pursuant to which certain investors purchased 3,747,125 shares of Vermillion common stock at a price of $1.40 per share. Vermillion also issued warrants to purchase shares of common stock at a price of $0.125 per warrant share in the private placement. Net proceeds of the private placement were approximately $5,100,000 after deducting offering expenses. The warrants are exercisable for 2,810,338 shares of Vermillion common stock at $1.80 per share . The warrants may be exercised from time to time beginning August 17, 2017 and expire on the fifth anniversary of the date of issuance or, if earlier, five business days after Vermillion delivers notice that the closing price per share of its common stock exceeded the exercise price for 20 consecutive trading days during the exercise period . The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximately $385,556,000 at December 31, 201 6 . The Company expects to incur a net loss in 201 7 as well . The Company’s management believes that successful achievement of the business objectives will require additional financing. The Company expects to raise capital through a variety of sources, which may include the exercise of common stock warrants, ( e.g. , the warrants to purchase 4,166,659 shares of Vermillion common stock at $2.00 per share, which warrants were issued in December 2014 and expire on December 23, 2017), public and private equity offerings , debt financing, collaborati on s, licensing arrangements, grants and government funding and strategic alliances . However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity and that could have a material adverse effect on the business, results of operations and financial condition. There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations. However, management believes that the current working capital position as of the date of these financial statements will be sufficient to meet the Company’s working capital needs for at least the next twelve months. Management expects cash from product and ASPiRA IVD sales to be the Company’s only material, recurring source of cash in 201 7 . Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated in consolidation . Use of Estimates The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The primary estimates underlying the Company’s consolidated financial statements include assumptions regarding revenue recognition as well as variables used in calculating the fair value of the Company’s equity awards, income taxes and contingent liabilities. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less from the date of purchase, which are readily convertible into known amounts of cash and are so near to their maturity that they present an insignificant risk of changes in value because of interest rate changes. Highly liquid investments that are considered cash equivalents include money market funds, certificates of deposits, treasury bills and commercial paper. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities.  Fair Value Measurement Accounting Standards Codification (“ASC ”) Topic 820 , Fair Value and Measurements (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 - Quoted prices in active markets for identical assets or liabilities. Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation.  Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains cash and cash equivalents in recognized financial institutions in the United States. The funds are insured by the FDIC up to a maximum of $250,000 , but are otherwise unprotected. The Company has not experienced any losses associated with deposits of cash and cash equivalents. The Company does not invest in derivative instruments or engage in hedging activities.  Accounts receivable Accounts receivable are derived from sales made to customers located in North America. The Company performs ongoing credit evaluations of its customer’s financial condition and generally does not require collateral. The Company maintains an allowance for doubtful accounts based upon the expected collectability of accounts receivable. Accounts receivable at December 31, 201 6 was from 16 customers. Accounts receivable at December 31, 201 5 was from 14 customer s . Property and Equipment Property and equipment are carried at cost less accumulated depreciation and amortization. Property and equipment are depreciated when placed into service using the straight-line method over the estimated useful lives, generally three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized. Revenue Recognition Product Revenue: The Company has adopted ASC 954-605, Health Care Entities—Revenue Recognition, as revenue from laboratory services has become significant to the Company . The Company's product revenue is generated by performing diagnostic services using its OVA1 and Overa tests, and the service is completed upon the delivery of test results to the prescribing physician. The Company recognizes revenue related to billings for Medicare and commercial payers on an accrual basis, net of contractual and other adjustments, when amounts that will ultimately be realized can be estimated. Until a contract has been negotiated with a commercial payer or governmental program, the OVA1 and Overa tests may or may not be covered by these entities' existing reimbursement policies. In addition, patients do not enter into direct agreements with the Company that commit them to pay any portion of the cost of the tests in the event that their insurance declines to reimburse the Company. In the absence of an agreement with the patient or other clearly enforceable legal right to demand payment from the patient, the related revenue is only recognized upon cash receipt.  Estimates of amounts that the Company will ultimately realize require significant judgment by management. Some patients have out-of-pocket costs for amounts not covered by their insurance carrier, and the Company may bill the patient directly for these amounts in the form of co-payments and co-insurance in accordance with the patient’s health plan. Some payers may not cover the OVA1 or Overa test as ordered by the prescribing physician under their reimbursement policies. The Company pursues reimbursement from such patients on a case-by-case basis. In the absence of contracted reimbursement coverage or the ability to estimate the amount that will ultimately be realized for the Company's services, revenue is recognized when cash is received.  Service Revenue: The Company’s service revenue is generated by performing IVD trial services for third-party customers. In accordance with SAB Topic 13, service revenue is recognized when the following revenue recognition criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.  License Revenue: Under the terms of the secured line of credit with Quest Diagnostics, which was terminated on March 11, 2015, portions of the borrowed principal amounts were forgiven upon achievement of certain milestones relating to the development, regulatory approval and commercialization of certain diagnostic tests (see Note 3). The Company accounted for forgiveness of principal debt balances as license revenues over the term of the exclusive sales period that Quest Diagnostics received upon commercialization of an approved diagnostic test as the Company did not have a sufficient history of product sales that provided a reasonable basis for estimating future product sales. License revenue was recognized on a straight-line basis over the original remaining period of Quest Diagnostics’ sales exclusivity ending in September 2015. The disputed exclusivity was formally terminated with Quest Diagnostics on March 11, 2015, and thus the remaining balance of deferred license revenue totaling $316,000 was recognized as of that date. Research and Development Costs Research and development costs are expensed as incurred. Research and development costs consist primarily of payroll and related costs, materials and supplies used in the development of new products, and fees paid to third parties that conduct certain research and development activities on the Company’s behalf. In addition, acquisitions of assets to be consumed in research and development are expensed as incurred as research and development costs. Software development costs incurred in the research and development of new products are expensed as incurred until technological feasibility is established. Patent Costs Costs incurred in filing, prosecuting and maintaining patents (principally legal fees) are expensed as incurred and recorded within general and administrative expenses on the Consolidated Statements of Operations. Such costs aggregated approximately $308,000 and $215,000 for the years ended December 31, 201 6 and 201 5 , respectively. Stock-Based Compensation The Company records the fair value of non-cash stock-based compensation costs for stock options and stock purchase rights related to the Amended and Restated 2010 Stock Incentive Plan, as amended (the “2010 Plan”). The Company estimates the fair value of stock options using a Black-Scholes option valuation model which requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore are subject to management's judgment. The expected life of options is based on historical data of actual experience with the options granted and represents the period of time that the options granted are expected to be outstanding. This data includes employees’ expected exercise and post-vesting employment termination behaviors. The expected stock price volatility was estimated using a combination of historical and peer group volatility for a blended volatility in deriving the expected volatility assumption through December 31, 2015 . Beginning January 1, 2016, expected stock price volatility is estimated using Company historical volatility only. The Company made an assessment that blended volatility was more representative of future stock price trends than just using historical or peer group volatility, which corresponds to the expected life of the options , through December 31, 2015. Beginning January 1, 2016, the Company made an assessment that Company historic volatility is more representative of future stock price trends than just using blended volatility. The expected dividend yield is based on the estimated annual dividends that are expected to be paid over the expected life of the options as a percentage of the market value of Vermillion common stock as of the grant date. The risk-free interest rate for the expected life of the options granted is based on the United States Treasury yield curve in effect as of the grant date. The Company uses the straight-line method to amortize the fair value over the vesting period of the award. The Company also records the fair value of non-cash stock-based compensation costs for equity instruments issued to non-employees. The cost for these options is recalculated each reporting period using a Black-Scholes option valuation model. A change in assumptions used in the calculations, including changes in the fair value of common stock, can result in significant changes in the amounts recorded from one reporting period to another. Contingencies The Company accounts for contingencies in accordance with ASC 450 Contingencies ("ASC 450") which requires that an estimated loss from a loss contingency be accrued when (i) information available prior to issuance of the financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) when the amount of the loss can be reasonably estimated. Accounting for contingencies such as legal and contract dispute matters requires the use of management’s judgment. Management believes that the Company’s accruals for these matters are adequate. Nevertheless, the actual loss from a loss contingency might differ from management’s estimates.  Income Taxes The Company accounts for income taxes using the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and the tax bases of assets and liabilities using the current tax laws and rates. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized. ASC Topic 740, Income Taxes clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, and disclosure. The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related liability lines in the Consolidated Balance Sheets. Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock adjusted for the dilutive effect of common stock equivalent shares outstanding during the period. Common stock equivalents consist of stock options, restricted stock units and stock warrants. Common equivalent shares are excluded from the computation in periods in which they have an anti-dilutive effect on earnings per share. Fair Value of Financial Instruments Financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term debt. The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term debt are at cost, which approximates fair value due to the short maturity of those instruments. Segment Reporting The Company operates one reportable segment.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2016
Recent Accounting Pronouncements [Abstract]
Recent Accounting Pronouncements	 NOTE 2: Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (the “ FASB ”) issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update changes the impairment model from the currently used incurred loss methodology to an expected loss methodology, which will result in the more timely recognition of losses. The ASU is scheduled to be effective in 2020. The Company is currently assessing the impact of this ASU on our financial statements. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718), Compensation - Stock Compensation. The new guidance simplifies several aspects of the accounting for share-based payments, including immediate recognition of all excess tax benefits and deficiencies in the income statement, changing the threshold to qualify for equity classification up to the employees' maximum statutory tax rates, allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur, and clarifying the classification on the statement of cash flows for the excess tax benefit and employee taxes paid when an employer withholds shares for tax-withholding purposes. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within that reporting period. The adoption of this standard is not expected to have a material effect on our financial statements. In February 2016, the FASB issued ASU 2016-02, Leases . The new standard establishes a right-of-use ( “ ROU ” ) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of the pending adoption of the new standard on the consolidated financial statements. In July 2015, the FASB issued ASU No. 2015-11 Inventory (Topic 330): Simplifying the Measurement of Inventory (“ASU No. 2015-11”). ASU 2015-11 changes the measurement of inventory from the lower of cost or market to the lower of cost and net realizable value. The amendments are effective prospectively for the fiscal years, and interim reporting periods within those years, beginning on or after December 15, 2016. The Company does not anticipate a material impact on its consolidated financial statements from the adoption of this ASU.  In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU No. 2014-09”). ASU 2014-09 removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. This guidance requires that an entity depict the consideration by applying a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On April 1, 2015, the FASB voted for a one-year deferral of the effective date of the new revenue recognition standard, ASU No. 2014-09. On July 15, 2015, the FASB affirmed these changes, which requires public entities to apply the amendments in ASU 2014-09 for annual reporting beginning after December 15, 2017. Early adoption is permitted beginning after December 31, 2016, the original effective date in ASU 2014-09. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures.  

Strategic Alliance And Secured

Strategic Alliance And Secured Line Of Credit With Quest Diagnostics Incorporated	12 Months Ended
	Dec. 31, 2016
Strategic Alliance And Secured Line Of Credit With Quest Diagnostics Incorporated [Abstract]
Strategic Alliance And Secured Line Of Credit With Quest Diagnostics Incorporated	NOTE 3: Strategic Alliance And Secured Line Of Credit with Quest Diagnostics Incorporated In July 2005, the Company entered into a Strategic Alliance Agreement (as amended, the “Strategic Alliance Agreement”) with Quest Diagnostics to develop and commercialize diagnostic tests from the Company’s product pipeline. In connection with the Strategic Alliance Agreement, the Company entered into a credit agreement with Quest Diagnostics, pursuant to which Quest Diagnostics provided the Company with a $10,000,000 secured line of credit to be used to pay for certain costs and expenses related to activities under the Strategic Alliance Agreement . The credit agreement provided for the forgiveness of portions of the amounts borrowed under the secured line of credit upon the achievement of certain milestones related to the development, regulatory approval and commercialization of certain diagnostic tests. Through December 31, 2014, the entire loan was either repaid or forgiven except for $1,106,000 which was in dispute. The dispute regarding the balance of the loan was resolved on March 11, 2015 for a payment to Quest Diagnostics totaling $1,069,000 . As a result of this settlement, the Company recognized one-time items during the year ended December 31, 2015, including product revenue of $163,000 , license revenue of $202,000 , gain on extinguishment of debt of $37,000 and reversal of other liabilities totaling $41,000 . In March 2015, the Company reached an agreement with Quest Diagnostics that terminated the Strategic Alliance Agreement and the Company’s prior loan agreement with Quest Diagnostics. The Company also entered into a commercial agreement with Quest Diagnostics. Pursuant to this agreement, all OVA1 U.S. testing services for Quest Diagnostics customers were transferred to Vermillion’s wholly-owned subsidiary, ASPiRA LABS, as of August 10, 2015. Pursuant to this agreement, as amended as of March 11 , 2017, Quest Diagnostics is continuing to provide blood draw and logistics support by transporting specimens from its clients to ASPiRA LABS for testing through at least March 11, 201 8 in exchange for a market value fee. Per the terms of the new commercial agreement, the Company will not offer to existing or future Quest Diagnostics customers tests that Quest Diagnostics offers. On June 17, 2015, the Company entered into a Share Repurchase Agreement (the “Share Repurchase Agreement”) with Quest Diagnostics. Pursuant to the Share Repurchase Agreement, the Company purchased from Quest Diagnostics 860,595 shares of Vermillion common stock for a total purchase price of $1,290,892 , or $1.50 per share. The price per share was agreed to in principle in March 2015 and based upon a simple average of the closing prices per share of Vermillion common stock for a trailing 60-day period at that time. This price was then reduced by a negotiated discount. Subsequently, the common stock repurchased from Quest Diagnostics was retired.  Accounts receivable from Quest Diagnostics totaled $0 and $1,000 at December 31, 201 6 and 201 5 , respectively. 

Property And Equipment

Property And Equipment	12 Months Ended
	Dec. 31, 2016
Property And Equipment [Abstract]
Property And Equipment	Note 4: Property and Equipment T he components of property and equipment as of December 31, 201 6 and 201 5 were as follo ws :     December 31,  (in thousands) 2016 2015  Machinery and equipment $ 1,381 $ 841  Demonstration equipment 39 39  Computer equipment and software 1,029 428  Furniture and fixtures 127 41  Leasehold improvements 704 36  Construction in progress - 773  Gross property and equipment 3,280 2,158  Accumulated depreciation and amortization (1,369) (654)  Property and equipment, net $ 1,911 $ 1,504  Depreciation expense for property and equipment was $723,000 and $291,000 for the years ended December 31, 2016 and 2015, respectively. The accumulated amortization of assets under capital lease obligations was $116,000 and the net book value of assets under capital lease obligations was $116,000 as of December 31, 2016. The accumulated amortization of assets under capital lease obligations was $39,000 and the net book value of assets under capital lease obligations was $193,000 as of December 31, 2015.  Construction in progress represented $289,000 in leasehold improvements and $484,000 in information technology build-out at our Trumbull, Connecticut facility in 2015. The facility was occupied and in operation beginning in January 2016.

Accured Liabilities

Accured Liabilities	12 Months Ended
	Dec. 31, 2016
Accrued Liabilities [Abstract]
Accrued Liabilities	NOTE 5 : Accrued Liabilities The components of accrued liabilities as of December 31, 2016 and 20 15 were as follows:      December 31,  (in thousands) 2016 2015  Payroll and benefits related expenses $ 541 $ 798  Collaboration and research agreements expenses 414 339  Professional services 217 717  Tax-related liabilities 4 40  Other accrued liabilities 288 314  Total accrued liabilities $ 1,464 $ 2,208 

Commitments, Contingencies And

Commitments, Contingencies And Debt	12 Months Ended
	Dec. 31, 2016
Commitments, Contingencies And Debt [Abstract]
Commitments, Contingencies And Debt	NOTE 6: Commitments , Contingencies and debt As of December 31, 2016, the annual amounts of future minimum payments under certain of the Company’s contractual obligations were:     Payments Due by Period  (in thousands) Total Less Than 1 Year 1-3 Years 3-5 Years More Than 5 Years  Operating Leases $ 592 $ 169 $ 247 $ 176 $ -  Capital Leases 61 41 20 - -  Total accrued liabilities $ 653 $ 210 $ 267 $ 176 $ -   In addition, the Company has minimum royalty obligations (described below in non-cancelable collaboration obligations and other commitments) and minimum quantities of reagent purchases from the manufacturer of certain laboratory instruments. Development L oan On March 22, 2016, the Company entered into the Loan Agreement with the DECD, pursuant to which the Company may borrow up to $4,000,000 from the DECD. Proceeds from the loan were utilized primarily to fund the build-out, information technology infrastructure and other costs related to the Company’s Trumbull, Connecticut facility and operations. The loan bears interest at a fixed rate of 2.0% per annum and requires equal monthly payments of principal and interest until maturity, which occurs on April 15, 2026 . As security for the loan, the Company has granted the DECD a blanket security interest in the Company’s personal and intellectual property. The DECD’s security interest in the Company’s intellectual property may be subordinated to a qualified institutional lender. Under the terms of the Loan Agreement, the Company may be eligible for forgiveness of up to $2,000,000 of the principal amount of the loan if the Company achieves certain job creation and retention milestones by March 1, 2018. Conversely, if the Company is unable to meet these job creation milestones, namely, hiring 40 full time employees with a specified average annual salary within the allotted timeframe and retaining those employees for a two year period or does not maintain the Company’s Connecticut operations for a period of 10 years, the DECD may require early repayment of a portion or all of the loan depending on job attainment as compared to the required amount plus a penalty of 5% . An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement . The Agreement provides that the remaining $2,000,000 will be advanced if and when the Company achieves certain future milestones including meeting a specified Company revenue target and meeting the job creation milestone described above. The loan may be prepaid at any time without premium or penalty . The balance of the DECD loan was $1,849,000 at December 31, 2016.  Operating Leases The Company leases facilities to support its business of discovering, developing and commercializing diagnostic tests in the fields of gynecologic disease, including its principal facility and CLIA laboratory located in Austin, Texas. As of December 31, 2016 there was an Austin, Texas lease which included an annual base rent of $67,000 and annual estimated common area charges, taxes and insurance of 39,000 . The lease expires on May 31, 2017 . In October 2015, the Company entered a lease agreement for a facility in Trumbull, Connecticut. The lease includes initial payments for the buildout of leasehold improvements to the office space, which are estimated to be approximately $438,000 . The term of the lease is five years beginning after the initial date of occupancy in January 2016 and a rent abatement period of five months. The lease includes an aggregate annual base rent of $32,000 and annual estimated common area charges, taxes and insurance of $91,000 . Rental expense under operating leases for the years ended December 31, 201 6 and 201 5 totaled $234,000 and $190,000 , respectively. Capital Lease In April 2015, the Company leased a laboratory instrument for a total initial payment of $125,000 and ongoing payments of approximately $3,500 per month for 36 months after delivery. The agreement also requires minimum annual purchases of reagents from the manufacturer of the equipment. The laboratory instrument was placed into service on July 1, 2015. The accumulated amortization of assets under capital lease obligations was $116,000 and the net book value of assets under capital lease obligations was $116,000 as of December 31, 201 6 . The accumulated amortization of assets under capital lease obligations was $39,000 and the net book value of assets under capital lease obligations was $193,000 as of December 31, 2015. Non - cancelable Collaboration Obligations and Other Commitments The Company ha d a research collaboration agreement with The Johns Hopkins University School of Medicine (“JHU”) directed at the discovery and validation of biomarkers in human subjects, including but not limited to clinical application of biomarkers in the understanding, diagnosis and management of human diseas e . This agreement expired on March 31, 2016. Collaboration expenses under the JHU collaboration were $264,000 and $600,000 for the years ended December 31, 201 6 and 201 5 , respectively. Collaboration expenses under the JHU collaboration are included in research and development expenses. In addition, under the terms of the amended research collaboration agreement, Vermillion is required to pay the greater of 4% royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of $57,500 . R oyalty expense for the years ended December 31, 201 6 and 201 5 totaled $92,000 and $74,000 , respectively. Contingent Liabilities F rom time to time, the Company is involved in legal proceedings and regulatory proceedings arising from operations. The Company establish es reserves for specific liabilities in connection with legal actions that management deem s to be probable and estimable. The Company is not currently a party to any proceeding, the adverse outcome of which would have a material adverse effect on the Company’s financial position or results of operations.

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2016
Common Stock [Abstract]
Common Stock	NOTE 7: Common Stock 2017 Private Placement On February 17, 2017 , the Company completed a private placement pursuant to which certain investors purchased 3,747,125 shares of Vermillion common stock at a price of $1.40 per share. Vermillion also issued warrants to purchase shares of common stock at a price of $0.125 per warrant share in the private placement. Net proceeds of the private placement were approximately $5,100,000 after deducting offering expenses. The warrants are exercisable for 2,810,338 shares of Vermillion common stock at $1.80 per share . The warrants may be exercised from time to time beginning August 17, 2017 and expire on the fifth anniversary of the date of issuance or, if earlier, five business days after Vermillion delivers notice that the closing price per share of its common stock exceeded the exercise price for 20 consecutive trading days during the exercise period . The sale of common stock and issuance of warrants qualified for equity treatment under GAAP. The respective values of the warrants and common stock were calculated using their relative fair values and classified under common stock and additional paid-in capital. The value ascribed to the warrants is $804,000 and to the common stoc k is approximately $4,296,000 . 2015 Registered Offering On July 17, 2015 the Company completed the sale of 9,602,500 shares of Vermillion common stock, including 1,252,500 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, in an underwritten public offering at a price of $1.96 per share. The Company received net proceeds from the offering of $17,495,000 after deducting underwriting discounts and offering expenses.   Warrants Warrants outstanding as of December 31, 201 6 and 201 5 were as follows:     Exercise Price Number of Shares Outstanding under Warrant  Issuance Date Expiration Date per Share December 31, 2016 December 31, 2015  May 13, 2013 May 13, 2016 $ 1.46 - 413,359  May 1, 2014 April 30, 2016 $ 4.70 - 7,000  December 23, 2014 December 23, 2017 $ 2.00 4,166,659 4,166,659  4,166,659 4,629,018  

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2016
Loss Per Share [Abstract]
Loss Per Share	 NOTE 8 : Loss Per Share The reconciliation of the numerators and denominators of basic and diluted loss per share for the years ended December 31, 2016 and 2015 was as fol lows :    Loss Shares Per Share  (In thousands, except per share data) (Numerator) (Denominator) Amount  Year ended December 31, 2015:  Net loss - basic $ (19,115) 47,124,261 $ (0.41)  Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards - -  Net loss - diluted $ (19,115) 47,124,261 $ (0.41)   Year ended December 31, 2016:  Net loss - basic $ (14,968) 52,197,969 $ (0.29)  Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards - -  Net loss - diluted $ (14,968) 52,197,969 $ (0.29)   Due to net losses for the years ended December 31, 2016 and 2015, diluted loss per share is calculated using the weighted average number of common shares outstanding and excludes the effects of potential shares of common stock that are antidilutive. The potential shares of common stock that have been excluded from the diluted loss per share calculation above for the years ended December 31, 2016 and 2015 were as follows:     Year Ended December 31,  2016 2015  Stock options 3,451,073 3,317,811  Stock warrants 4,166,659 4,587,018  Unvested restricted stock awards 7,752 -  Potential common shares 7,625,484 7,904,829 

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2016
Employee Benefit Plans [Abstract]
Employee Benefit Plans	 NOTE 9: Employee Benefit Plans 2000 Stock Plan Under the Amended and Restated 2000 Stock Plan (the “2000 Plan”), options could be granted at prices not lower than 85% and 100% of the fair market value of the common stock for non-statutory and statutory stock options, respectively. Options generally vest monthly over a period of four years and unexercised options generally expire ten years from the date of grant. The authority of Vermillion’s Board of Directors to grant new stock options and awards under the 2000 Plan terminated in 2010. There were no stock options under the 2000 Stock Plan exercised during the year ended December 31, 2016 or 2015. No additional shares of common stock were reserved for future option grants under the 2000 Plan.  2010 Stock Incentive Plan Under the 2010 Plan, employees, directors and consultants of the Company are eligible to receive awards. The 2010 Plan is administered by the Compensation Committee of Vermillion ’s Board of Directors. The 2010 Plan permits the granting of a variety of awards, including stock options, share appreciation rights, restricted shares, restricted share units, unrestricted shares, deferred share units, performance and cash-settled awards, and dividend equivalent rights. On June 18 , 2015 , Vermillion ’s stockholders approved an increase of 4,500,000 in the number of shares available for issuance under the 2010 Plan for a total of 8,122,983 shares. Unexercised options generally expire ten years from the date of grant. Options to purchase 3,541 and 59,583 shares of common stock were exercised during the year ended December 31, 201 6 and 201 5 , respectively. During the year ended December 31, 201 6 , Vermillion issued to Vermillion ’s Board of Directors 197,727 shares of restricted stock from the 2010 Plan having a fair value of $310,000 as payment for services rendered in 201 6 . The Company also issued to certain consultants 14,165 shares of restricted stock from the 2010 Plan having a fair value of $18,000 . During the year ended December 31, 201 5 , Vermillion issued to Vermillion ’s Board of Directors 195,781 shares of restricted stock from the 2010 Plan having a fair value of $401,000 as payment for services rendered in 201 5 . Subsequent to December 31, 2016, the Company awarded 131,250 shares of restricted stock from the 2010 Plan having a fair value of approximately $281,000 to Vermillion’s Board of Directors as payment for services in 2017. The restricted stock vests 50% on June 1, 2017 and 25% each on September 1, 2017 and December 1, 2017 . The Company also granted approximately 986,000 stock options with an exercise price of $2.14 per share to certain of the Company’s officers, employees and consultants. These stock options generally vest 25% on each of the four anniversaries of the grant date. I n addition, the Company granted certain officers options to purchase 250,000 shares of Vermillion common stock with an exercise price of $2.14 per share with performance-based vesting based on certain metrics through December 31, 2017. These options vest 25% on each of the four anniversaries of the grant date if the performance-based metrics are met. The activity related to shares available for grant under the 2000 Plan and the 2010 Plan for the years ended December 31, 201 6 and 201 5 was as follows:     2000 Stock Plan 2010 Stock Option Plan Total  Shares available at December 31, 2014 - 737,434 737,434  Shares added 4,500,000 4,500,000  Options canceled 3,800 69,352 73,152  Reduction in shares reserved (3,800) - (3,800)  Options granted - (1,739,500) (1,739,500)  Restricted stock units granted - (195,781) (195,781)  Shares available at December 31, 2015 - 3,371,505 3,371,505  Options canceled 33,050 2,243,217 2,276,267  Reduction in shares reserved (33,050) - (33,050)  Options granted - (2,413,070) (2,413,070)  Restricted stock units granted - (211,892) (211,892)  Shares available at December 31, 2016 - 2,989,760 2,989,760   The stock option activity under the 2000 Plan and 2010 Plan for the years ended December 31, 201 6 and 201 5 was as follows:    Number of Shares Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Term  Options outstanding at December 31, 2014 1,711,046 $ 2.62 $ 178 7.82  Granted 1,739,500 1.99  Exercised (59,583) 1.62  Canceled (73,152) 3.29  Options outstanding at December 31, 2015 3,317,811 $ 2.29 $ 91 8.24  Granted 2,413,070 1.33  Exercised (3,541) 1.30  Canceled (2,276,267) 2.21  Options outstanding at December 31, 2016 3,451,073 $ 1.70 $ 41 8.46   Shares exercisable:  December 31, 2016 1,084,140 $ 2.29 $ - 6.96  Shares expected to vest:  December 31, 2016 1,940,885 $ 1.43 $ 41 9.15   The range of exercise prices for options outstanding and exercisable at December 31, 201 6 is as follows:     Exercise Price Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Life in Years Options Exercisable Weighted Average Exercise Price  $ 0.01 - $ 1.30 835,000 $ 0.94 9.78 4,010 $ 1.30  1.31 - 1.64 1,258,668 1.52 8.82 223,958 1.57  1.65 - 2.08 932,414 1.95 7.58 501,199 1.97  2.09 - 11.55 424,991 3.17 6.76 354,973 3.21   $ 0.01 - $ 11.55 3,451,073 $ 1.70 8.46 1,084,140 $ 2.29      (in thousands) Total Intrinsic Value of Options Exercised Total Fair Value of Vested Options  Year ended December 31, 2016 $ 1 $ 1,562  Year ended December 31, 2015 $ 13 $ 1,864   Stock-based Compensation Employee Stock-based Compensation Expense The assumptions used to calculate the fair value of options granted under the 2010 Plan that were incorporated in the Black-Scholes pricing model for the years ended December 31, 201 6 and 201 5 were as follows:      Year Ended December 31,  2016 2015  Dividend yield - % - %  Volatility 77 % 78 %  Risk-free interest rate 0.96 % 1.76 %  Expected lives (years) 4.0 6.0  Weighted average fair value $ 0.77 $ 1.37  The allocation of employee stock-based compensation expense by functional area for the years ended December 31, 201 6 and 201 5 was as follows:     Year Ended December 31,  (in thousands) 2016 2015  Cost of sales $ 93 $ 40  Research and development 71 137  Sales and marketing 101 209  General and administrative 759 825  Total $ 1,024 $ 1,211  As of December 31, 201 6 , total unrecognized compensation cost related to un vested stock option awards was approximately $1,808,000 and the related weighted average period over which it is expected to be recognized was 2.44 years. 401(k) Plan The Company’s 401(k) Plan allows eligible employees to defer up to an annual limit of the lesser of 90.0% of eligible compensation or a maximum contribution amount subject to the Internal Revenue Service annual contribution limit. The Company is not required to make contributions under the 401(k) Plan. During the years ended December 31, 2016 and 2015 , the Company did not contribute to the 401(k) Plan.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Taxes [Abstract]
Income Taxes	NOTE 10: Income Taxes There was no income tax expense or benefit for the years ended December 31, 2016 or 2015 because of net losses during those years. These net losses were generated from domestic operations.  Based on the available objective evidence and uncertainty about the timing and amount of any future profits, the Company has provided a full valuation allowance against our net deferred tax assets at December 31, 2016 and 2015. The components of net deferred tax assets at December 31, 2016 and 2015 were as follows:      Year Ended December 31,  (in thousands) 2016 2015  Deferred tax assets:  Net operating losses $ 22,861 $ 65,341  Amortization - R&D intangibles 5,327 5,919  Other 2,903 3,007  Total deferred tax assets 31,091 74,267  Valuation allowance (31,091) (74,267)  Deferred tax assets $ - $ -   Deferred tax liabilities:  Other $ - $ -  Deferred tax liabilities $ - $ -   Net deferred tax asset $ - $ -   The reconciliation of the statutory federal income tax rate to the Company’s effective tax rate for the years ended December 31, 2016 and 2015 was as follows:      Year Ended December 31,  2016 2015  Tax at federal statutory rate 34 % 34 %  State tax, net of federal benefit 1 2  Valuation allowance 291 (36)  Change in warrant valuation - -  Net operating loss and credit reduction due to section 382 limitations (327) -  Permanent items (2) (1)  Other 3 1  Effective income tax rate - % - %  As of December 31, 2016, the Company had pre-tax net operating loss carryforwards of approximately 59,000,000 for federal and $167,000,000 for state tax purposes. If not utilized, these carryforwards begin to expire in 2026 for federal purposes and 2017 for state purposes. In 2017, approximately $12,000,000 of the Company’s state net operating loss will expire. As of December 31, 2015, we had a net operating loss of approximately $185,000,000 for federal and $160,000,000 for state tax purposes. The Company’s ability to use net operating loss and tax credit carryforwards may be restricted due to ownership change limitations, as required by Section 382 of the Internal Revenue Code of 1986, as amended (“Section 382”), as well as similar state provisions. These ownership changes may also limit the amount of net operating loss and tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. We believe that Section 382 ownership changes occurred as a result of our follow-on public offerings in 2011, 2013 and 2015. Any limitation may result in the expiration of a portion of the net operating loss and credit carryforwards before utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of our valuation allowance . Due to the existence of a valuation allowance, it is not expected that such limitations, if any, will have an impact on our results of operations or financial position. We believe that it is more likely than not that the benefit from certain deferred tax assets will not be realized due to the h istory of our operating losses. In recognition of this risk, we have provided a valuation allowance on the deferred tax assets relating to these assets. The valuation allowance was $ 31 ,000,000 and $74,000,000 at December 31, 2016 and 2015, respectively. The de crease of $43,000,000 between 2016 and 2015 is primarily due to adjustments to the deferred tax assets related to the net operating losses. The Company files income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. The Company has not been audited by the Internal Revenue Service or any state income or franchise tax agency. As of December 31, 2016, the Company’s federal returns for the years ended 2013 through the current period and most state returns for the years ended 2012 through the current period are still open to examination. In addition, all of the net operating loss carryforwards and research and development credits generated in years earlier than 2013 and 2012, respectively, are still subject to Internal Revenue Service audit. The federal and California tax returns for the year ended December 31, 2015 reflect research and development carryforwards of $5,335,000 and $5,246,000 , respectively. The Company has recognized additional deferred tax assets for federal and California research and development credits of $95,000 and $71,000 for the year ended December 31, 2016, respectively. As of December 31, 2016, our gross unrecognized tax benefits are approximately $10,747,000 which are attributable to research and development credit carryforwards . A reconciliation of the change in the Company’s unrecognized tax benefits is as follows:     (in thousands) Federal Tax State Tax Total  Balance at December 31, 2014 $ 5,188 $ 5,135 $ 10,323  Increase in tax position during 2015 147 111 258  Decrease due to expirations - - -  Balance at December 31, 2015 $ 5,335 $ 5,246 $ 10,581  Increase in tax position during 2016 95 71 166  Decrease due to expirations - - -  Balance at December 31, 2016 $ 5,430 $ 5,317 $ 10,747  The increase for the year ended December 31, 2016 relates to a position taken in the current year. The increase for the year ended December 31, 2015 is related to tax positions taken during 2015 and prior years. If the $11 million of unrecognized income tax benefit is recognized, approximately $11 million would impact the effective tax rate in the period in which each of the benefits is recognized. We do not expect our unrecognized tax benefits to change significantly over the next 12 months. We recognize interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the consolidated statement of operations and comprehensive loss. We have not recorded any interest or penalties as a result of uncertain tax positions as of December 31, 2016 and 2015. Accrued interest and penalties would be included within the related liability in the consolidated balance sheet.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 11: Related Party Transactions On January 18, 201 6 , the Company entered into a consulting agreement with David Schreiber, a member of Vermillion’s Board of Directors. Pursuant to the terms of the consulting agreement, Mr. Schreiber provide d consulting services regarding business strategies and operational plans and was paid $375 per hour or a minimum of $51,750 for the period up to the expiration of the agreement on March 31, 2016. During the year ended December 31, 2016, Mr. Schreiber was paid $52,000 for services provided pursuant to the consulting agreement. 

Basis Of Presentation And Sig19

Basis Of Presentation And Significant Accounting And Reporting Policies (Policy)	12 Months Ended
	Dec. 31, 2016
Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]
Organization	Organization Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells the OVA1™ and Overa ™ risk of malignancy test s for ovarian cancer (“OVA1” and “Overa” ). Until August 10, 2015, the Company distributed OVA1 through Quest Diagnostics Incorporated (“Quest Diagnostics”) (see Note 3). Since August 10, 2015, the Company has distributed all tests through Vermillion’s wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, ASPiRA LABS, Inc . (“ASPiRA LABS”). The Company also offers in-vitro diagnostic (“IVD”) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (“ASPiRA IVD”), which was formed in April 2016. ASPiRA IVD is a specialized, CLIA certified, laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize high-complexity assays. ASPiRA IVD was built around a core of laboratory expertise and a United States Food and Drug Administration (“FDA”)-compliant quality system, and strives to deliver accurate and reliable results to its third-party customers suitable for FDA submission.
Liquidity	Liquidity I n July 2015 the Company completed the sale of 9,602,500 shares of Vermillion common stock, at a price to the public of $1.96 per share, including 1,252,500 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, in an underwritten public offering at a price of $1.96 per share. Net proceeds from the offering were approximately $17,495,000 after deducting underwriting discounts and offering expenses. As discussed in Note 6, on March 22, 2016, the Company entered into a loan agreement (the “Loan Agreement”) pursuant to which it may borrow up to $4,000,000 from the State of Connecticut Department of Economic and Community Development (“DECD”). An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. The remaining $2,000,000 will be advanced if and when the Company achieves certain future milestones. On February 17, 2017 , the Company completed a private placement pursuant to which certain investors purchased 3,747,125 shares of Vermillion common stock at a price of $1.40 per share. Vermillion also issued warrants to purchase shares of common stock at a price of $0.125 per warrant share in the private placement. Net proceeds of the private placement were approximately $5,100,000 after deducting offering expenses. The warrants are exercisable for 2,810,338 shares of Vermillion common stock at $1.80 per share . The warrants may be exercised from time to time beginning August 17, 2017 and expire on the fifth anniversary of the date of issuance or, if earlier, five business days after Vermillion delivers notice that the closing price per share of its common stock exceeded the exercise price for 20 consecutive trading days during the exercise period . The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximately $385,556,000 at December 31, 201 6 . The Company expects to incur a net loss in 201 7 as well . The Company’s management believes that successful achievement of the business objectives will require additional financing. The Company expects to raise capital through a variety of sources, which may include the exercise of common stock warrants, ( e.g. , the warrants to purchase 4,166,659 shares of Vermillion common stock at $2.00 per share, which warrants were issued in December 2014 and expire on December 23, 2017), public and private equity offerings , debt financing, collaborati on s, licensing arrangements, grants and government funding and strategic alliances . However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity and that could have a material adverse effect on the business, results of operations and financial condition. There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations. However, management believes that the current working capital position as of the date of these financial statements will be sufficient to meet the Company’s working capital needs for at least the next twelve months. Management expects cash from product and ASPiRA IVD sales to be the Company’s only material, recurring source of cash in 201 7 .
Basis Of Consolidation	Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated in consolidation
Use Of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The primary estimates underlying the Company’s consolidated financial statements include assumptions regarding revenue recognition as well as variables used in calculating the fair value of the Company’s equity awards, income taxes and contingent liabilities. Actual results could differ from those estimates.
Cash And Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less from the date of purchase, which are readily convertible into known amounts of cash and are so near to their maturity that they present an insignificant risk of changes in value because of interest rate changes. Highly liquid investments that are considered cash equivalents include money market funds, certificates of deposits, treasury bills and commercial paper. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities.
Fair Value Measurement	Fair Value Measurement Accounting Standards Codification (“ASC ”) Topic 820 , Fair Value and Measurements (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 - Quoted prices in active markets for identical assets or liabilities. Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation.
Concentration Of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains cash and cash equivalents in recognized financial institutions in the United States. The funds are insured by the FDIC up to a maximum of $250,000 , but are otherwise unprotected. The Company has not experienced any losses associated with deposits of cash and cash equivalents. The Company does not invest in derivative instruments or engage in hedging activities.
Accounts Receivable	Accounts receivable Accounts receivable are derived from sales made to customers located in North America. The Company performs ongoing credit evaluations of its customer’s financial condition and generally does not require collateral. The Company maintains an allowance for doubtful accounts based upon the expected collectability of accounts receivable. Accounts receivable at December 31, 201 6 was from 16 customers. Accounts receivable at December 31, 201 5 was from 14 customer s .
Property And Equipment	Property and Equipment Property and equipment are carried at cost less accumulated depreciation and amortization. Property and equipment are depreciated when placed into service using the straight-line method over the estimated useful lives, generally three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.
Revenue Recognition	Revenue Recognition Product Revenue: The Company has adopted ASC 954-605, Health Care Entities—Revenue Recognition, as revenue from laboratory services has become significant to the Company . The Company's product revenue is generated by performing diagnostic services using its OVA1 and Overa tests, and the service is completed upon the delivery of test results to the prescribing physician. The Company recognizes revenue related to billings for Medicare and commercial payers on an accrual basis, net of contractual and other adjustments, when amounts that will ultimately be realized can be estimated. Until a contract has been negotiated with a commercial payer or governmental program, the OVA1 and Overa tests may or may not be covered by these entities' existing reimbursement policies. In addition, patients do not enter into direct agreements with the Company that commit them to pay any portion of the cost of the tests in the event that their insurance declines to reimburse the Company. In the absence of an agreement with the patient or other clearly enforceable legal right to demand payment from the patient, the related revenue is only recognized upon cash receipt.  Estimates of amounts that the Company will ultimately realize require significant judgment by management. Some patients have out-of-pocket costs for amounts not covered by their insurance carrier, and the Company may bill the patient directly for these amounts in the form of co-payments and co-insurance in accordance with the patient’s health plan. Some payers may not cover the OVA1 or Overa test as ordered by the prescribing physician under their reimbursement policies. The Company pursues reimbursement from such patients on a case-by-case basis. In the absence of contracted reimbursement coverage or the ability to estimate the amount that will ultimately be realized for the Company's services, revenue is recognized when cash is received.  Service Revenue: The Company’s service revenue is generated by performing IVD trial services for third-party customers. In accordance with SAB Topic 13, service revenue is recognized when the following revenue recognition criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.  License Revenue: Under the terms of the secured line of credit with Quest Diagnostics, which was terminated on March 11, 2015, portions of the borrowed principal amounts were forgiven upon achievement of certain milestones relating to the development, regulatory approval and commercialization of certain diagnostic tests (see Note 3). The Company accounted for forgiveness of principal debt balances as license revenues over the term of the exclusive sales period that Quest Diagnostics received upon commercialization of an approved diagnostic test as the Company did not have a sufficient history of product sales that provided a reasonable basis for estimating future product sales. License revenue was recognized on a straight-line basis over the original remaining period of Quest Diagnostics’ sales exclusivity ending in September 2015. The disputed exclusivity was formally terminated with Quest Diagnostics on March 11, 2015, and thus the remaining balance of deferred license revenue totaling $316,000 was recognized as of that date.
Research And Development Costs	Research and Development Costs Research and development costs are expensed as incurred. Research and development costs consist primarily of payroll and related costs, materials and supplies used in the development of new products, and fees paid to third parties that conduct certain research and development activities on the Company’s behalf. In addition, acquisitions of assets to be consumed in research and development are expensed as incurred as research and development costs. Software development costs incurred in the research and development of new products are expensed as incurred until technological feasibility is established.
Patent Costs	Patent Costs Costs incurred in filing, prosecuting and maintaining patents (principally legal fees) are expensed as incurred and recorded within general and administrative expenses on the Consolidated Statements of Operations. Such costs aggregated approximately $308,000 and $215,000 for the years ended December 31, 201 6 and 201 5 , respectively.
Stock-Based Compensation	Stock-Based Compensation The Company records the fair value of non-cash stock-based compensation costs for stock options and stock purchase rights related to the Amended and Restated 2010 Stock Incentive Plan, as amended (the “2010 Plan”). The Company estimates the fair value of stock options using a Black-Scholes option valuation model which requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore are subject to management's judgment. The expected life of options is based on historical data of actual experience with the options granted and represents the period of time that the options granted are expected to be outstanding. This data includes employees’ expected exercise and post-vesting employment termination behaviors. The expected stock price volatility was estimated using a combination of historical and peer group volatility for a blended volatility in deriving the expected volatility assumption through December 31, 2015 . Beginning January 1, 2016, expected stock price volatility is estimated using Company historical volatility only. The Company made an assessment that blended volatility was more representative of future stock price trends than just using historical or peer group volatility, which corresponds to the expected life of the options , through December 31, 2015. Beginning January 1, 2016, the Company made an assessment that Company historic volatility is more representative of future stock price trends than just using blended volatility. The expected dividend yield is based on the estimated annual dividends that are expected to be paid over the expected life of the options as a percentage of the market value of Vermillion common stock as of the grant date. The risk-free interest rate for the expected life of the options granted is based on the United States Treasury yield curve in effect as of the grant date. The Company uses the straight-line method to amortize the fair value over the vesting period of the award. The Company also records the fair value of non-cash stock-based compensation costs for equity instruments issued to non-employees. The cost for these options is recalculated each reporting period using a Black-Scholes option valuation model. A change in assumptions used in the calculations, including changes in the fair value of common stock, can result in significant changes in the amounts recorded from one reporting period to another.
Contingencies	Contingencies The Company accounts for contingencies in accordance with ASC 450 Contingencies ("ASC 450") which requires that an estimated loss from a loss contingency be accrued when (i) information available prior to issuance of the financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) when the amount of the loss can be reasonably estimated. Accounting for contingencies such as legal and contract dispute matters requires the use of management’s judgment. Management believes that the Company’s accruals for these matters are adequate. Nevertheless, the actual loss from a loss contingency might differ from management’s estimates.
Income Taxes	  Income Taxes The Company accounts for income taxes using the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and the tax bases of assets and liabilities using the current tax laws and rates. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized. ASC Topic 740, Income Taxes clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, and disclosure. The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related liability lines in the Consolidated Balance Sheets.
Net Loss Per Share	 Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock adjusted for the dilutive effect of common stock equivalent shares outstanding during the period. Common stock equivalents consist of stock options, restricted stock units and stock warrants. Common equivalent shares are excluded from the computation in periods in which they have an anti-dilutive effect on earnings per share.
Fair Value Of Financial Instruments	Fair Value of Financial Instruments Financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term debt. The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and short-term debt are at cost, which approximates fair value due to the short maturity of those instruments.
Segment Reporting	Segment Reporting The Company operates one reportable segment.

Property And Equipment (Tables)

Property And Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Property And Equipment [Abstract]
Components Of Property And Equipment	   December 31,  (in thousands) 2016 2015  Machinery and equipment $ 1,381 $ 841  Demonstration equipment 39 39  Computer equipment and software 1,029 428  Furniture and fixtures 127 41  Leasehold improvements 704 36  Construction in progress - 773  Gross property and equipment 3,280 2,158  Accumulated depreciation and amortization (1,369) (654)  Property and equipment, net $ 1,911 $ 1,504 

Accurued Liabilities (Tables)

Accurued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Accrued Liabilities [Abstract]
Components Of Accrued Liabilities	   December 31,  (in thousands) 2016 2015  Payroll and benefits related expenses $ 541 $ 798  Collaboration and research agreements expenses 414 339  Professional services 217 717  Tax-related liabilities 4 40  Other accrued liabilities 288 314  Total accrued liabilities $ 1,464 $ 2,208 

Commitments, Contingencies An22

Commitments, Contingencies And Debt (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments, Contingencies And Debt [Abstract]
Summary Of Commitments And Contigencies	   Payments Due by Period  (in thousands) Total Less Than 1 Year 1-3 Years 3-5 Years More Than 5 Years  Operating Leases $ 592 $ 169 $ 247 $ 176 $ -  Capital Leases 61 41 20 - -  Total accrued liabilities $ 653 $ 210 $ 267 $ 176 $ -   

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2016
Common Stock [Abstract]
Schedule Of Warrants Outstanding	   Exercise Price Number of Shares Outstanding under Warrant  Issuance Date Expiration Date per Share December 31, 2016 December 31, 2015  May 13, 2013 May 13, 2016 $ 1.46 - 413,359  May 1, 2014 April 30, 2016 $ 4.70 - 7,000  December 23, 2014 December 23, 2017 $ 2.00 4,166,659 4,166,659  4,166,659 4,629,018  

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2016
Loss Per Share [Abstract]
Reconciliation Of Numerators And Denominators Of Basic And Diluted Loss Per Share	   Loss Shares Per Share  (In thousands, except per share data) (Numerator) (Denominator) Amount  Year ended December 31, 2015:  Net loss - basic $ (19,115) 47,124,261 $ (0.41)  Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards - -  Net loss - diluted $ (19,115) 47,124,261 $ (0.41)   Year ended December 31, 2016:  Net loss - basic $ (14,968) 52,197,969 $ (0.29)  Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards - -  Net loss - diluted $ (14,968) 52,197,969 $ (0.29)  
Potential Shares Of Common Stock Excluded From Diluted Loss Per Share Calculation	   Year Ended December 31,  2016 2015  Stock options 3,451,073 3,317,811  Stock warrants 4,166,659 4,587,018  Unvested restricted stock awards 7,752 -  Potential common shares 7,625,484 7,904,829 

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2016
Employee Benefit Plans [Abstract]
Activity Related to Shares Available for Grant Under the 2000 Plan and 2010 Plan	   2000 Stock Plan 2010 Stock Option Plan Total  Shares available at December 31, 2014 - 737,434 737,434  Shares added 4,500,000 4,500,000  Options canceled 3,800 69,352 73,152  Reduction in shares reserved (3,800) - (3,800)  Options granted - (1,739,500) (1,739,500)  Restricted stock units granted - (195,781) (195,781)  Shares available at December 31, 2015 - 3,371,505 3,371,505  Options canceled 33,050 2,243,217 2,276,267  Reduction in shares reserved (33,050) - (33,050)  Options granted - (2,413,070) (2,413,070)  Restricted stock units granted - (211,892) (211,892)  Shares available at December 31, 2016 - 2,989,760 2,989,760  
Stock Option Activity Under 2000 Plan and 2010 Plan	   Number of Shares Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Term  Options outstanding at December 31, 2014 1,711,046 $ 2.62 $ 178 7.82  Granted 1,739,500 1.99  Exercised (59,583) 1.62  Canceled (73,152) 3.29  Options outstanding at December 31, 2015 3,317,811 $ 2.29 $ 91 8.24  Granted 2,413,070 1.33  Exercised (3,541) 1.30  Canceled (2,276,267) 2.21  Options outstanding at December 31, 2016 3,451,073 $ 1.70 $ 41 8.46   Shares exercisable:  December 31, 2016 1,084,140 $ 2.29 $ - 6.96  Shares expected to vest:  December 31, 2016 1,940,885 $ 1.43 $ 41 9.15 
Range of Exercise Prices for Options Outstanding and Exercisable	   Exercise Price Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Life in Years Options Exercisable Weighted Average Exercise Price  $ 0.01 - $ 1.30 835,000 $ 0.94 9.78 4,010 $ 1.30  1.31 - 1.64 1,258,668 1.52 8.82 223,958 1.57  1.65 - 2.08 932,414 1.95 7.58 501,199 1.97  2.09 - 11.55 424,991 3.17 6.76 354,973 3.21   $ 0.01 - $ 11.55 3,451,073 $ 1.70 8.46 1,084,140 $ 2.29 
Fair Value of Options Vested	   (in thousands) Total Intrinsic Value of Options Exercised Total Fair Value of Vested Options  Year ended December 31, 2016 $ 1 $ 1,562  Year ended December 31, 2015 $ 13 $ 1,864 
Assumptions Used to Calculate Fair Value of Options Granted Under 2010 Plan	   Year Ended December 31,  2016 2015  Dividend yield - % - %  Volatility 77 % 78 %  Risk-free interest rate 0.96 % 1.76 %  Expected lives (years) 4.0 6.0  Weighted average fair value $ 0.77 $ 1.37 
Allocation of Stock-Based Compensation Expense by Functional Area	   Year Ended December 31,  (in thousands) 2016 2015  Cost of sales $ 93 $ 40  Research and development 71 137  Sales and marketing 101 209  General and administrative 759 825  Total $ 1,024 $ 1,211 

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Taxes [Abstract]
Components Of Deferred Tax Assets (Liabilities)	   Year Ended December 31,  (in thousands) 2016 2015  Deferred tax assets:  Net operating losses $ 22,861 $ 65,341  Amortization - R&D intangibles 5,327 5,919  Other 2,903 3,007  Total deferred tax assets 31,091 74,267  Valuation allowance (31,091) (74,267)  Deferred tax assets $ - $ -   Deferred tax liabilities:  Other $ - $ -  Deferred tax liabilities $ - $ -   Net deferred tax asset $ - $ - 
Reconciliation Of Statutory Federal Income Tax Rate	   Year Ended December 31,  2016 2015  Tax at federal statutory rate 34 % 34 %  State tax, net of federal benefit 1 2  Valuation allowance 291 (36)  Change in warrant valuation - -  Net operating loss and credit reduction due to section 382 limitations (327) -  Permanent items (2) (1)  Other 3 1  Effective income tax rate - % - % 
Reconciliation Of Change In Unrecognized Tax Benefits	   (in thousands) Federal Tax State Tax Total  Balance at December 31, 2014 $ 5,188 $ 5,135 $ 10,323  Increase in tax position during 2015 147 111 258  Decrease due to expirations - - -  Balance at December 31, 2015 $ 5,335 $ 5,246 $ 10,581  Increase in tax position during 2016 95 71 166  Decrease due to expirations - - -  Balance at December 31, 2016 $ 5,430 $ 5,317 $ 10,747 

Basis Of Presentation And Summa

Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies (Details)	Feb. 17, 2017USD ($)$ / sharesshares	Apr. 15, 2016USD ($)	Jul. 17, 2015USD ($)$ / sharesshares	Jul. 15, 2015USD ($)$ / sharesshares	Mar. 11, 2015USD ($)	Dec. 31, 2016USD ($)customersegment$ / sharesshares	Dec. 31, 2015USD ($)customer$ / sharesshares	Mar. 22, 2016USD ($)
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Common stock, shares issued | shares			9,602,500	9,602,500		52,328,492	52,113,059
Shares issued to underwriters | shares			1,252,500	1,252,500
Price per share | $ / shares			$ 1.96	$ 1.96		$ 0.001	$ 0.001
Proceeds from sale of common stock, net of issuance costs			$ 17,495,000	$ 17,495,000
Proceeds From Issuance Of Private Placement							$ 17,495,000
Warrants outstanding to purchase shares | shares						4,166,659	4,629,018
Exercise price of warrants | $ / shares						$ 2
Initial proceeds from loan						$ 1,967,000
Accumulated deficit						$ (385,556,000)	$ (370,588,000)
Accounts receivable, number of customers | customer						16	14
Licenses Revenue							$ 316,000
Patent costs						$ 308,000	$ 215,000
Number of reportable segments | segment						1
Quest Diagnostics [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Licenses Revenue					$ 316,000
DECD [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Total borrowing amount								$ 4,000,000
Initial proceeds from loan		$ 2,000,000
Remaining loan amount								$ 2,000,000
Subsequent Event [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Common stock, shares issued | shares	3,747,125
Price per share | $ / shares	$ 1.40
Issued a warrant to purchase common stock with a cost | $ / shares	$ 0.125
Proceeds From Issuance Of Private Placement	$ 5,100,000
Warrants outstanding to purchase shares | shares	2,810,338
Exercise price of warrants | $ / shares	$ 1.80
Minimum [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Useful life						3 years
Maximum [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Useful life						5 years

Strategic Alliance And Secure28

Strategic Alliance And Secured Line Of Credit With Quest Diagnostics Incorporated (Details) - USD ($)	Jun. 17, 2015	Mar. 11, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Line of Credit Facility [Line Items]
Secured line of credit, liability			$ 182,000
Repayment of short-term debt				$ 1,069,000
Product			2,320,000	1,861,000
License				316,000
Gain on extinguishment of debt				37,000
Shares authorized for repurchase	$ 860,595
Total purchase price of shares acquired	$ 1,290,892
Shares acquired, price per share	$ 1.50
Quest Diagnostics [Member]
Line of Credit Facility [Line Items]
Quest Diagnostics provided secured line of credit			10,000,000
Secured line of credit, liability					$ 1,106,000
Repayment of short-term debt		$ 1,069,000
Product				163,000
License				202,000
Gain on extinguishment of debt				37,000
Decrease to other current liabilities				41,000
Accounts receivable from related party			$ 0	$ 1,000

Property And Equipment (Narrati

Property And Equipment (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Depreciation expense for property and equipment	$ 723,000	$ 291,000
Accumulated amortization	1,369,000	654,000
Net book value	1,911,000	1,504,000
Assets Under Capital Leases [Member]
Property, Plant and Equipment [Line Items]
Accumulated amortization	116,000	39,000
Net book value	$ 116,000	193,000
Trumbull, Connecticut Facility [Member] | Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Construction in progress		289,000
Trumbull, Connecticut Facility [Member] | Information Technology [Member]
Property, Plant and Equipment [Line Items]
Construction in progress		$ 484,000

Property And Equipment (Compone

Property And Equipment (Components Of Property And Equipment) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 3,280	$ 2,158
Accumulated depreciation and amortization	(1,369)	(654)
Property and equipment, net	1,911	1,504
Machinery And Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	1,381	841
Demonstration Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	39	39
Computer Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	1,029	428
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	127	41
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 704	36
Construction In Progress [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment		$ 773

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accrued Liabilities [Abstract]
Payroll and benefits related expenses	$ 541	$ 798
Collaboration and research agreements expenses	414	339
Professional services	217	717
Tax-related liabilities	4	40
Other accrued liabilities	288	314
Total accrued liabilities	$ 1,464	$ 2,208

Commitments, Contingencies An32

Commitments, Contingencies And Debt (Narrative) (Details)	Apr. 15, 2016USD ($)	Apr. 30, 2015USD ($)	Dec. 31, 2016USD ($)employee	Dec. 31, 2015USD ($)	Mar. 22, 2016USD ($)
Commitments And Contingencies [Line Items]
Initial proceeds from loan			$ 1,967,000
Operating leases rental expense			234,000	190,000
Total initial payment			30,000	13,000
Accumulated amortization			1,369,000	654,000
Net book value			1,911,000	1,504,000
Royalty expense			92,000	74,000
Research and development			2,172,000	3,751,000
Austin, Texas facility [Member]
Commitments And Contingencies [Line Items]
Annual base rent			67,000
Annual estimated common area charges, taxes and insurance			$ 39,000
Lease expiration date			May 31, 2017
Trumbull, Connecticut Facility [Member]
Commitments And Contingencies [Line Items]
Annual base rent			$ 32,000
Annual estimated common area charges, taxes and insurance			91,000
Leasehold improvements			$ 438,000
Lease term			5 years
Rent abatement period			5 months
Johns Hopkins University School Of Medicine [Member]
Commitments And Contingencies [Line Items]
Percent of royalty paid			4.00%
Minimum royalty payment			$ 57,500
Research and development			$ 264,000	600,000
DECD [Member]
Commitments And Contingencies [Line Items]
Total borrowing amount					$ 4,000,000
Fixed rate per annum					2.00%
Amount eligible for forgiveness					$ 2,000,000
Job creation, number of employees | employee			40
Job creation, term			2 years
Debt, maturity term			10 years
Debt penalty			5.00%
Initial proceeds from loan	$ 2,000,000
Remaining loan amount					$ 2,000,000
Balance of DECD loan			$ 1,849,000
Assets Under Capital Leases [Member]
Commitments And Contingencies [Line Items]
Total initial payment		$ 125,000
Monthly payment for acquisition for equipment		$ 3,500
Number of payments for purchase production of assets			36 months
Accumulated amortization			$ 116,000	39,000
Net book value			$ 116,000	$ 193,000

Commitments, Contingencies An33

Commitments, Contingencies And Debt (Summary Of Commitments And Contigencies) (Details) $ in Thousands	Dec. 31, 2016USD ($)
Other Commitments [Line Items]
Total accrued liabilities	$ 653
Total accrued liabilities, Less Than 1 Year	210
Total accrued liabilities, 1-3 Years	267
Total accrued liabilities, 3-5 Years	176
Total accrued liabilities, More Than 5 Years
Operating Lease [Member]
Other Commitments [Line Items]
Total accrued liabilities	592
Total accrued liabilities, Less Than 1 Year	169
Total accrued liabilities, 1-3 Years	247
Total accrued liabilities, 3-5 Years	176
Total accrued liabilities, More Than 5 Years
Capital Leases [Member]
Other Commitments [Line Items]
Total accrued liabilities	61
Total accrued liabilities, Less Than 1 Year	41
Total accrued liabilities, 1-3 Years	20
Total accrued liabilities, 3-5 Years
Total accrued liabilities, More Than 5 Years

Common Stock (Narrative) (Detai

Common Stock (Narrative) (Details) - USD ($)	Feb. 17, 2017	Jul. 17, 2015	Jul. 15, 2015	Dec. 31, 2016	Dec. 31, 2015
Common Stock Equity [Line Items]
Common stock, shares issued		9,602,500	9,602,500	52,328,492	52,113,059
Shares issued to underwriters		1,252,500	1,252,500
Price per share		$ 1.96	$ 1.96	$ 0.001	$ 0.001
Proceeds From Issuance Of Private Placement					$ 17,495,000
Warrants outstanding to purchase shares				4,166,659	4,629,018
Exercise price of warrants				$ 2
Common stock value				$ 52,000	$ 52,000
Aggregate proceeds from common stock issued					17,373,000
Net proceeds after deducting offering costs from common stock issued		$ 17,495,000	$ 17,495,000
Common Stock [Member]
Common Stock Equity [Line Items]
Aggregate proceeds from common stock issued					$ 10,000
Subsequent Event [Member]
Common Stock Equity [Line Items]
Common stock, shares issued	3,747,125
Price per share	$ 1.40
Issued a warrant to purchase common stock with a cost	$ 0.125
Proceeds From Issuance Of Private Placement	$ 5,100,000
Warrants outstanding to purchase shares	2,810,338
Exercise price of warrants	$ 1.80
Fair value of warrants issued	$ 804,000
Common stock value	$ 4,296,000

Common Stock (Schedule Of Warra

Common Stock (Schedule Of Warrants Outstanding) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Class of Warrant or Right [Line Items]
Exercise Price per Share	$ 2
Number of Shares Outstanding under Warrant	4,166,659	4,629,018
May 13, 2013 - May 13, 2016 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	May 13, 2013
Expiration Date	May 13, 2016
Exercise Price per Share	$ 1.46
Number of Shares Outstanding under Warrant		413,359
May 1, 2014 - April 30, 2016 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	May 1, 2014
Expiration Date	Apr. 30, 2016
Exercise Price per Share	$ 4.70
Number of Shares Outstanding under Warrant		7,000
December 23, 2014 - December 23, 2017 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Dec. 23, 2014
Expiration Date	Dec. 23, 2017
Exercise Price per Share	$ 2
Number of Shares Outstanding under Warrant	4,166,659	4,166,659

Loss Per Share (Reconciliation

Loss Per Share (Reconciliation Of Numerators And Denominators Of Basic And Diluted Loss Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Loss Per Share [Abstract]
Net loss-basic	$ (14,968)	$ (19,115)
Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards
Net loss-diluted	$ (14,968)	$ (19,115)
Net loss-basic	52,197,969	47,124,261
Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards
Net loss-diluted	52,197,969	47,124,261
Basic Per Share Amount	$ (0.29)	$ (0.41)
Diluted Per Share Amount	$ (0.29)	$ (0.41)

Loss Per Share (Potential Share

Loss Per Share (Potential Shares Of Common Stock Excluded From Diluted Loss Per Share Calculation) (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	7,625,484	7,904,829
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	3,451,073	3,317,811
Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	4,166,659	4,587,018
Unvested Restricted Stock Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	7,752

Employee Benefit Plans (Narrati

Employee Benefit Plans (Narrative) (Details) - USD ($)	Jun. 18, 2015	Mar. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, exercised				3,541	59,583
Stock options, shares of common stock remained outstanding				3,451,073	3,317,811	1,711,046
Additional shares authorized					4,500,000
Total unrecognized compensation cost related to nonvested stock option awards				$ 1,808,000
Weighted average period over which unrecognized cost expected to be recognized				2 years 5 months 9 days
401(k) Plan, percentage for compensation defer				90.00%
401 (k) contributions				$ 0	$ 0
2000 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options vesting period				4 years
Stock options, expiration period				10 years
Stock options, exercised				0	0
Maximum common stock provides for issuance under stock plan				0
2000 Stock Plan [Member] | Statutory Stock Options | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option grant price, percentage of fair market value of common stock				100.00%
2000 Stock Plan [Member] | Nonstatutory Stock Options | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option grant price, percentage of fair market value of common stock				85.00%
2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, expiration period				10 years
Stock options, exercised				3,541	59,583
Maximum common stock provides for issuance under stock plan				8,122,983
Additional shares authorized	4,500,000
2010 Stock Incentive Plan [Member] | Board Of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted share units granted					195,781
Restricted share units granted				197,727
Fair value of restricted share units				$ 310,000	$ 401,000
2010 Stock Incentive Plan [Member] | Certain Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted share units granted				14,165
Fair value of restricted share units				$ 18,000
Subsequent Event [Member] | 2010 Stock Incentive Plan [Member] | Certain Company Officers And Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted		986,000
Stock options granted, exercise price		$ 2.14
Subsequent Event [Member] | 2010 Stock Incentive Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted share units granted		131,250
Fair value of restricted share units		$ 281,000
Share-based Compensation Award, Tranche One [Member] | Subsequent Event [Member] | 2010 Stock Incentive Plan [Member] | Certain Company Officers And Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
Share-based Compensation Award, Tranche One [Member] | Subsequent Event [Member] | 2010 Stock Incentive Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		50.00%
Share-based Compensation Award, Tranche Two [Member] | Subsequent Event [Member] | 2010 Stock Incentive Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
Share-based Compensation Award, Tranche Three [Member] | Subsequent Event [Member] | 2010 Stock Incentive Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
Forecast [Member] | 2010 Stock Incentive Plan [Member] | Certain Company Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted			250,000
Stock options granted, exercise price			$ 2.14
Forecast [Member] | Share-based Compensation Award, Tranche One [Member] | 2010 Stock Incentive Plan [Member] | Certain Company Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage			25.00%

Employee Benefit Plans (Activit

Employee Benefit Plans (Activity Related To Shares Available For Grant) (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available at beginning of period	3,371,505	737,434
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		4,500,000
Options canceled	2,276,267	73,152
Reduction in shares reserved	(33,050)	(3,800)
Options granted	(2,413,070)	(1,739,500)
Restricted stock units granted	(211,892)	(195,781)
Shares available at End of period	2,989,760	3,371,505
2000 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available at beginning of period
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized
Options canceled	33,050	3,800
Reduction in shares reserved	(33,050)	(3,800)
Options granted
Restricted stock units granted
Shares available at End of period
2010 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available at beginning of period	3,371,505	737,434
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		4,500,000
Options canceled	2,243,217	69,352
Reduction in shares reserved
Options granted	(2,413,070)	(1,739,500)
Restricted stock units granted	(211,892)	(195,781)
Shares available at End of period	2,989,760	3,371,505

Employee Benefit Plans (Summary

Employee Benefit Plans (Summary Of Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Number of Shares
Number of Shares Beginning Balance	3,317,811	1,711,046
Number of Shares Granted	2,413,070	1,739,500
Number of Shares Exercised	(3,541)	(59,583)
Number of Shares Canceled	(2,276,267)	(73,152)
Number of Shares Ending Balance	3,451,073	3,317,811	1,711,046
Number of Shares Shares exercisable	1,084,140
Number of Shares Shares expected to vest	1,940,885
Weighted Average Exercise Price
Weighted Average Exercise Price Beginning Balance	$ 2.29	$ 2.62
Weighted Average Exercise Price Granted	1.33	1.99
Weighted Average Exercise Price Exercised	1.30	1.62
Weighted Average Exercise Price Canceled	2.21	3.29
Weighted Average Exercise Price Ending Balance	1.70	$ 2.29	$ 2.62
Weighted Average Exercise Price Shares exercisable	2.29
Weighted Average Exercise Price Shares expected to vest	$ 1.43
Aggregate Intrinsic Value	$ 41	$ 91	$ 178
Aggregate Intrinsic Value Shares expected to vest	$ 41
Weighted Average Remaining Contractual Term	8 years 5 months 16 days	8 years 2 months 27 days	7 years 9 months 26 days
Weighted Average Remaining Contractual Term Shares exercisable	6 years 11 months 16 days
Weighted Average Remaining Contractual Term Shares expected to vest	9 years 1 month 24 days

Employee Benefit Plans (Stock O

Employee Benefit Plans (Stock Options Outstanding And Exercisable) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	$ 0.01
Exercise Price Upper Range	$ 11.55
Options Outstanding	3,451,073	3,317,811	1,711,046
Weighted Average Exercise Price	$ 1.70	$ 2.29	$ 2.62
Weighted Average Remaining life	8 years 5 months 16 days
Options Exercisable	1,084,140
Weighted Average Exercise Price	$ 2.29
$0.01 - $1.30 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	0.01
Exercise Price Upper Range	$ 1.30
Options Outstanding	835,000
Weighted Average Exercise Price	$ 0.94
Weighted Average Remaining life	9 years 9 months 11 days
Options Exercisable	4,010
Weighted Average Exercise Price	$ 1.30
$1.31 - $1.64 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	1.31
Exercise Price Upper Range	$ 1.64
Options Outstanding	1,258,668
Weighted Average Exercise Price	$ 1.52
Weighted Average Remaining life	8 years 9 months 26 days
Options Exercisable	223,958
Weighted Average Exercise Price	$ 1.57
$1.65 - $2.08 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	1.65
Exercise Price Upper Range	$ 2.08
Options Outstanding	932,414
Weighted Average Exercise Price	$ 1.95
Weighted Average Remaining life	7 years 6 months 29 days
Options Exercisable	501,199
Weighted Average Exercise Price	$ 1.97
$2.09 - $11.55 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	2.09
Exercise Price Upper Range	$ 11.55
Options Outstanding	424,991
Weighted Average Exercise Price	$ 3.17
Weighted Average Remaining life	6 years 9 months 4 days
Options Exercisable	354,973
Weighted Average Exercise Price	$ 3.21

Employee Benefit Plans (Fair Va

Employee Benefit Plans (Fair Value of Options Vested) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Employee Benefit Plans [Abstract]
Total Intrinsic Value of Options Exercised	$ 1	$ 13
Total Fair Value of Vested Options	$ 1,562	$ 1,864

Employee Benefit Plans (Assumpt

Employee Benefit Plans (Assumptions Used to Calculate Fair Value Of Options Granted) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Employee Benefit Plans [Abstract]
Dividend yield
Volatility	77.00%	78.00%
Risk-free interest rate	0.96%	1.76%
Expected lives (years)	4 years	6 years
Weighted average fair value	$ 0.77	$ 1.37

Employee Benefit Plans (Allocat

Employee Benefit Plans (Allocation Of Employee Stock-Based Compensation Expense By Functional Area) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 115	$ 40
Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	71	137
Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	108	209
General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	885	841
Employee Stock-based Compensation [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,024	1,211
Employee Stock-based Compensation [Member] | Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	93	40
Employee Stock-based Compensation [Member] | Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	71	137
Employee Stock-based Compensation [Member] | Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	101	209
Employee Stock-based Compensation [Member] | General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 759	$ 825

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Line Items]
Income tax benefit (expense)	$ 0	$ 0
Operating loss, net carryforwards expiration amount	12,000,000
additional deferred tax assets	166,000	258,000
Valuation allowance	31,091,000	74,267,000
Increase in valuation allowance	43,000,000
Gross unrecognized tax benefits	10,747,000	10,581,000	$ 10,323,000
Total Unrecognized income tax benefit, affecting effective tax rate if recognized	11
Accrued interest and penalties	0	0
Research And Development Carryforward [Member]
Income Taxes [Line Items]
Gross unrecognized tax benefits	10,747,000
Federal Tax [Member]
Income Taxes [Line Items]
Operating loss carryforwards	59,000,000	185,000,000
additional deferred tax assets	95,000	147,000
Gross unrecognized tax benefits	5,430,000	5,335,000	5,188,000
Federal Tax [Member] | Research And Development Carryforward [Member]
Income Taxes [Line Items]
additional deferred tax assets	95,000
Gross unrecognized tax benefits		5,335,000
State Tax [Member]
Income Taxes [Line Items]
Operating loss carryforwards	167,000,000	160,000,000
additional deferred tax assets	71,000	111,000
Gross unrecognized tax benefits	5,317,000	5,246,000	$ 5,135,000
State Tax [Member] | Research And Development Carryforward [Member]
Income Taxes [Line Items]
additional deferred tax assets	$ 71,000
Gross unrecognized tax benefits		$ 5,246,000
Minimum [Member] | Federal Tax [Member]
Income Taxes [Line Items]
Operating loss carryforwards expiration date	Dec. 31, 2026
Minimum [Member] | State Tax [Member]
Income Taxes [Line Items]
Operating loss carryforwards expiration date	Dec. 31, 2017

Income Taxes (Components Of Def

Income Taxes (Components Of Deferred Tax Assets (Liabilities)) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating losses	$ 22,861	$ 65,341
Amortization - R&D intangibles	5,327	5,919
Other	2,903	3,007
Total deferred tax assets	31,091	74,267
Valuation allowance	(31,091)	(74,267)
Deferred tax assets
Deferred tax liabilities:
Other
Deferred tax liabilities
Net deferred tax asset

Income Taxes (Reconciliation Of

Income Taxes (Reconciliation Of Statutory Federal Income Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Abstract]
Tax at federal statutory rate	34.00%	34.00%
State tax, net of federal benefit	1.00%	2.00%
Valuation allowance	291.00%	(36.00%)
Change in warrant valuation
Net operating loss and credit reduction due to section 382 limitations	(327.00%)
Permanent items	(2.00%)	(1.00%)
Other	3.00%	1.00%
Effective income tax rate

Income Taxes (Reconciliation 48

Income Taxes (Reconciliation Of Change In Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Contingency [Line Items]
Beginning Balance	$ 10,581	$ 10,323
Increase in tax position	166	258
Decrease due to expirations
Ending Balance	10,747	10,581
Federal Tax [Member]
Income Tax Contingency [Line Items]
Beginning Balance	5,335	5,188
Increase in tax position	95	147
Decrease due to expirations
Ending Balance	5,430	5,335
State Tax [Member]
Income Tax Contingency [Line Items]
Beginning Balance	5,246	5,135
Increase in tax position	71	111
Decrease due to expirations
Ending Balance	$ 5,317	$ 5,246

Related Party Transactions (Det

Related Party Transactions (Details) - Director [Member]	Jan. 18, 2016USD ($)$ / H	Dec. 31, 2016USD ($)
Related Party Transaction [Line Items]
Consulting agreement fee per hour | $ / H	375
Consulting service expenses		$ 52,000
Minimum [Member]
Related Party Transaction [Line Items]
Consulting agreement payable	$ 51,750